Sunday, October 4, 2026

HANG SENG INDEX Went Up By Over 3% In The Last 5 Sessions

HANG SENG INDEX Went Up By Over 3% In The Last 5 Sessions

(VIANEWS) - HANG SENG INDEX (HSI) has been up by 3.04% for the last 5 sessions. At 22:08 EST on Monday, 5 June, HANG SENG INDEX (HSI) is $19,115.24.

Concerning HANG SENG INDEX's yearly highs and lows, it's 30.95% up from its 52-week low and 15.8% down from its 52-week high.

Volatility

HANG SENG INDEX's last week, last month's, and last quarter's current intraday variation average was a positive 0.65%, a negative 0.30%, and a positive 1.20%, respectively.

HANG SENG INDEX's highest amplitude of average volatility was 2.03% (last week), 1.28% (last month), and 1.20% (last quarter), respectively.

Index Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, HANG SENG INDEX's is considered to be oversold (<=20).

News about

  • Nasdaq 100 signal: continues to see impulsive move higher - 05 June 2023. According to DailyForex on Monday, 5 June, "Potential signal: I believe that the NASDAQ 100 will continue to see buyers jump into it, at least until the bubble pops. ", "Because of this, for a short-term trade I like the idea of buying the NASDAQ 100 on tips, especially if I can get involved somewhere near the 14,300 level. "

More news about HANG SENG INDEX (HSI).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com